Tracking Parkinson's disease over one year with multimodal magnetic resonance imaging in a group of older patients with moderate disease

PLoS ONE

Volumn 10, Issue 12, 2015, Pages

  Melzer, Tracy R ^a,b   Myall, Daniel J ^a   MacAskill, Michael R ^a,b   Pitcher, Toni L ^a,b   Livingston, Leslie ^a,b   Watts, Richard ^c   Keenan, Ross J ^a,d   Dalrymple Alford, John C ^a,b,e   Anderson, Tim J ^a,b,f  

^a NEW ZEALAND BRAIN RESEARCH INSTITUTE   (New Zealand)

^b UNIVERSITY OF OTAGO   (New Zealand)

^c UNIVERSITY OF VERMONT   (United States)

^d Christchurch Radiology Group   (New Zealand)

^e UNIVERSITY OF CANTERBURY   (New Zealand)

^f CHRISTCHURCH HOSPITAL   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

AGED; ARTICLE; BRAIN ATROPHY; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DIFFUSION TENSOR IMAGING; DISEASE DURATION; FEMALE; GRAY MATTER; HUMAN; INFERIOR TEMPORAL CORTEX; LONGITUDINAL STUDY; MALE; MEDIAL TEMPORAL LOBE; MULTIMODAL IMAGING; NEUROIMAGING; NEUROPSYCHOLOGICAL TEST; NUCLEAR MAGNETIC RESONANCE IMAGING; ORBITAL CORTEX; PARKINSON DISEASE; PERFUSION WEIGHTED IMAGING; VOXEL BASED MORPHOMETRY; WHITE MATTER; BRAIN; COHORT ANALYSIS; DISEASE COURSE; MIDDLE AGED; PATHOLOGY;

AGED; BRAIN; COHORT STUDIES; DISEASE PROGRESSION; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; PARKINSON DISEASE;

EID: 84958213585     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0143923     Document Type: Article

References (43)

1. Jack CR Jr., Knopman DS, Jagust WJ, Petersen RC, Weiner MW, Aisen PS, et al. Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. 2013; 12(2):207-16. doi: 10.1016/S1474-4422(12)70291-0 PMID: 23332364.
2. Melzer TR, Watts R, MacAskill MR, Pearson JF, Rueger S, Pitcher TL, et al. Arterial spin labelling reveals an abnormal cerebral perfusion pattern in Parkinson's disease. Brain. 2011; 134(Pt 3):845-55. PMID: 21310726. doi: 10.1093/brain/awq377.
3. Melzer TR, Watts R, MacAskill MR, Pitcher TL, Livingston L, Keenan R, et al. White matter microstructure deteriorates across cognitive stages in Parkinson disease. Neurology. 2013; 80(20):1841-9. doi: 10.1212/WNL.0b013e3182929f62 PMID: 23596076.
4. Melzer TR, Watts R, MacAskill MR, Pitcher TL, Livingston L, Keenan RJ, et al. Grey matter atrophy in cognitively impaired Parkinson's disease. J Neurol Neurosurg Psychiatry. 2012; 83(2):183-94.
5. Hattori T, Orimo S, Aoki S, Ito K, Abe O, Amano A, et al. Cognitive status correlates with white matter alteration in Parkinson's disease. Hum Brain Mapp. 2012; 33(3):727-39. PMID: 21495116. doi: 10. 1002/hbm.21245.
6. Weintraub D, Doshi J, Koka D, Davatzikos C, Siderowf AD, Duda JE, et al. Neurodegeneration across stages of cognitive decline in Parkinson disease. Arch Neurol. 2011; 68(12):1562-8. doi: 10.1001/archneurol.2011.725 PMID: 22159053.
7. Kamagata K, Motoi Y, Hori M, Suzuki M, Nakanishi A, Shimoji K, et al. Posterior hypoperfusion in Parkinson's disease with and without dementia measured with arterial spin labeling MRI. J Magn Reson Imaging. 2011; 33(4):803-7. doi: 10.1002/jmri.22515 PMID: 21448943.
8. Duncan GW, Firbank MJ, O'Brien JT, Burn DJ. Magnetic resonance imaging: A biomarker for cognitive impairment in Parkinson's disease? Mov Disord. 2013; 28(4):425-38. doi: 10.1002/mds.25352 PMID: 23450518.
9. Haller S, Nguyen D, Rodriguez C, Emch J, Gold G, Bartsch A, et al. Individual prediction of cognitive decline in mild cognitive impairment using support vector machine-based analysis of diffusion tensor imaging data. J Alzheimers Dis. 2010; 22(1):315-27. doi: 10.3233/JAD-2010-100840 PMID: 20847435.
10. Tabrizi SJ, Scahill RI, Durr A, Roos RA, Leavitt BR, Jones R, et al. Biological and clinical changes in premanifest and early stage Huntington's disease in the TRACK-HD study: The 12-month longitudinal analysis. Lancet Neurol. 2011; 10(1):31-42. PMID: 21130037. doi: 10.1016/S1474-4422(10)70276-3.
11. Di Filippo M, Anderson VM, Altmann DR, Swanton JK, Plant GT, Thompson AJ, et al. Brain atrophy and lesion load measures over 1 year relate to clinical status after 6 years in patients with clinically isolated syndromes. J Neurol Neurosurg Psychiatry. 2010; 81(2):204-8. PMID: 19744964. doi: 10.1136/jnnp.2009.171769.
12. Ibarretxe-Bilbao N, Junque C, Segura B, Baggio HC, Marti MJ, Valldeoriola F, et al. Progression of cortical thinning in early Parkinson's disease. Mov Disord. 2012; 27(14):1746-53. doi: 10.1002/mds.25240 PMID: 23124622.
13. Camicioli R, Sabino J, Gee M, Bouchard T, Fisher N, Hanstock C, et al. Ventricular dilatation and brain atrophy in patients with Parkinson's disease with incipient dementia. Mov Disord. 2011; 26(8):1443-50. Epub 2011/03/29. doi: 10.1002/mds.23700 PMID: 21442661.
14. Burton EJ, McKeith IG, Burn DJ, O'Brien JT. Brain atrophy rates in Parkinson's disease with and without dementia using serial magnetic resonance imaging. Mov Disord. 2005; 20(12):1571-6. PMID: 16116613.
15. Hu MT, White SJ, Chaudhuri KR, Morris RG, Bydder GM, Brooks DJ. Correlating rates of cerebral atrophy in Parkinson's disease with measures of cognitive decline. J Neural Transm. 2001; 108(5):571-80. PMID: 11459077.
16. Ramírez-Ruiz B, Martí M, Tolosa E, Bartrés-Faz D, Summerfield C, Salgado-Pineda P, et al. Longitudinal evaluation of cerebral morphological changes in Parkinson's disease with and without dementia. J Neurol. 2005; 252(11):1345-52. PMID: 15995795.
17. Baba T, Kikuchi A, Hirayama K, Nishio Y, Hosokai Y, Kanno S, et al. Severe olfactory dysfunction is a prodromal symptom of dementia associated with Parkinson's disease: a 3 year longitudinal study. Brain. 2012; 135(1):161-9. doi: 10.1093/brain/awr321.
18. Paviour DC, Price SL, Jahanshahi M, Lees AJ, Fox NC. Longitudinal MRI in progressive supranuclear palsy and multiple system atrophy: rates and regions of atrophy. Brain. 2006; 129(4):1040-9. doi: 10. 1093/brain/awl021.
19. Compta Y, Pereira JB, Rios J, Ibarretxe-Bilbao N, Junque C, Bargallo N, et al. Combined dementia-risk biomarkers in Parkinson's disease: a prospective longitudinal study. Parkinsonism Relat Disord. 2013; 19(8):717-24. Epub 2013/05/07. doi: 10.1016/j.parkreldis.2013.03.009 PMID: 23643469.
20. Lewis MM, Smith AB, Styner M, Gu H, Poole R, Zhu H, et al. Asymmetrical lateral ventricular enlargement in Parkinson's disease. Eur J Neurol. 2009; 16(4):475-81. doi: 10.1111/j.1468-1331.2008.02430. x PMID: 19187264.
21. Hanganu A, Bedetti C, Degroot C, Mejia-Constain B, Lafontaine AL, Soland V, et al. Mild cognitive impairment is linked with faster rate of cortical thinning in patients with Parkinson's disease longitudinally. Brain. 2014; 137(4):1120-9. Epub 2014/03/13. doi: 10.1093/brain/awu036 PMID: 24613932.
22. Tessa C, Lucetti C, Giannelli M, Diciotti S, Poletti M, Danti S, et al. Progression of brain atrophy in the early stages of Parkinson's disease: A longitudinal tensor-based morphometry study in de novo patients without cognitive impairment. Hum Brain Mapp. 2014; 35(8):3932-44. doi: 10.1002/hbm. 22449 PMID: 24453162.
23. Wen M-C, Ng A, Chander RJ, Au WL, Tan LCS, Kandiah N. Longitudinal brain volumetric changes and their predictive effects on cognition among cognitively asymptomatic patients with Parkinson's disease. Parkinsonism Relat Disord. 2015. doi: 10.1016/j.parkreldis.2015.02.014.
24. Ofori E, Pasternak O, Planetta PJ, Li H, Burciu RG, Snyder AF, et al. Longitudinal changes in freewater within the substantia nigra of Parkinson's disease. Brain. 2015; 138:2322-31. doi: 10.1093/brain/awv136 PMID: 25981960.
25. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry. 1992; 55(3):181-4. doi: 10.1136/jnnp.55.3.181 PMID: 1564476.
26. Goetz CG, Tilley BC, Shaftman SR, Stebbins GT, Fahn S, Martinez-Martin P, et al. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord. 2008; 23(15):2129-70. doi: 10.1002/mds.22340 PMID: 19025984.
27. Dalrymple-Alford JC, MacAskill MR, Nakas CT, Livingston L, Graham C, Crucian GP, et al. The MoCA: well-suited screen for cognitive impairment in Parkinson disease. Neurology. 2010; 75(19):1717-25. doi: 10.1212/WNL.0b013e3181fc29c9 PMID: 21060094.
28. Dalrymple-Alford JC, Livingston L, MacAskill MR, Graham C, Melzer TR, Watts R, et al. Characterizing mild cognitive impairment in Parkinson's disease. Mov Disord. 2011; 26(4):629-36. doi: 10.1002/mds. 23592 PMID: 21287603.
29. Litvan I, Goldman JG, Tröster AI, Schmand BA, Weintraub D, Petersen RC, et al. Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines. Mov Disord. 2012; 27(3):349-56. doi: 10.1002/mds.24893 PMID: 22275317.
30. Emre M, Aarsland D, Brown RG, Burn DJ, Duyckaerts C, Mizuno Y, et al. Clinical diagnostic criteria for dementia associated with Parkinson's disease. Mov Disord. 2007; 22(12):1689-707. PMID: 17542011.
31. Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE. Systematic review of levodopa dose equivalency reporting in Parkinson's disease. Mov Disord. 2010; 25(15):2649-53. Epub 2010/11/12. doi: 10.1002/mds.23429 PMID: 21069833.
32. Dai W, Garcia D, de Bazelaire C, Alsop DC. Continuous flow-driven inversion for arterial spin labeling using pulsed radio frequency and gradient fields. Magn Reson Med. 2008; 60(6):1488-97. doi: 10. 1002/mrm.21790 PMID: 19025913.
33. Ashburner J, Ridgway GR. Symmetric diffeomorphic modelling of longitudinal structural MRI. Frontiers in Neuroscience. 2013; 6:197. doi: 10.3389/fnins.2012.00197 PMID: 23386806.
34. Smith SM, Zhang Y, Jenkinson M, Chen J, Matthews PM, Federico A, et al. Accurate, robust, and automated longitudinal and cross-sectional brain change analysis. Neuroimage. 2002; 17(1):479-89. PMID: 12482100.
35. Engvig A, Fjell AM, Westlye LT, Moberget T, Sundseth O, Larsen VA, et al. Memory training impacts short-term changes in aging white matter: A longitudinal diffusion tensor imaging study. Hum Brain Mapp. 2012; 33(10):2390-406. PMID: 21823209. doi: 10.1002/hbm.21370.
36. Smith SM, Jenkinson M, Johansen-Berg H, Rueckert D, Nichols TE, Mackay CE, et al. Tract-based spatial statistics: voxelwise analysis of multi-subject diffusion data. Neuroimage. 2006; 31(4):1487- 505. PMID: 16624579.
37. Winkler AM, Ridgway GR, Webster MA, Smith SM, Nichols TE. Permutation inference for the general linear model. Neuroimage. 2014; 92(0):381-97. doi: 10.1016/j.neuroimage.2014.01.060.
38. Smith SM, Nichols TE. Threshold-free cluster enhancement: addressing problems of smoothing, threshold dependence and localisation in cluster inference. Neuroimage. 2009; 44(1):83-98. doi: 10. 1016/j.neuroimage.2008.03.061 PMID: 18501637.
39. Nishio Y, Hirayama K, Takeda A, Hosokai Y, Ishioka T, Suzuki K, et al. Corticolimbic gray matter loss in Parkinson's disease without dementia. Eur J Neurol. 2010; 17(8):1090-7. PMID: 20298422. doi: 10. 1111/j.1468-1331.2010.02980.x.
40. Song SK, Lee JE, Park H-J, Sohn YH, Lee JD, Lee PH. The pattern of cortical atrophy in patients with Parkinson's disease according to cognitive status. Mov Disord. 2011; 26(2):289-96. doi: 10.1002/mds. 23477 PMID: 21370255.
41. Beyer MK, Janvin CC, Larsen JP, Aarsland D. A magnetic resonance imaging study of patients with Parkinson's disease with mild cognitive impairment and dementia using voxel-based morphometry. J Neurol Neurosurg Psychiatry. 2007; 78(3):254-9. doi: 10.1136/jnnp.2006.093849 PMID: 17028119.
42. Rossi ME, Ruottinen H, Saunamäki T, Elovaara I, Dastidar P. Imaging brain iron and diffusion patterns: A follow-up study of Parkinson's disease in the initial stages. Acad Radiol. 2014; 21(1):64-71. doi: 10. 1016/j.acra.2013.09.018 PMID: 24331266.
43. Borghammer P, Chakravarty M, Jonsdottir KY, Sato N, Matsuda H, Ito K, et al. Cortical hypometabolism and hypoperfusion in Parkinson's disease is extensive: probably even at early disease stages. Brain Struct Funct. 2010; 214(4):303-17. PMID: 20361208. doi: 10.1007/s00429-010-0246-0.